AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Aminosyn Ii 3.5% In Dextrose 5% In Plastic Container patents expire, and what generic alternatives are available?

Aminosyn Ii 3.5% In Dextrose 5% In Plastic Container is a drug marketed by Abbott, Hospira, and Hospira Inc. and is included in six NDAs.

The generic ingredient in AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER is amino acids; dextrose; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic, heptahydrate. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; dextrose; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic, heptahydrate profile page.

Summary for AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	3
NDAs:	6
DailyMed Link:	AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

US Patents and Regulatory Information for AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019506-001	Nov 7, 1986		DISCN	No	No
Abbott	AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic, heptahydrate	INJECTABLE;INJECTION	019564-001	Dec 16, 1986		DISCN	No	No
Abbott	AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019713-002	Sep 9, 1988		DISCN	No	No

Market Dynamics and Financial Trajectory for Aminosyn II 3.5% in Dextrose 5% in Plastic Container

Last updated: March 2, 2026

What Are the Market Drivers for Aminosyn II 3.5% in Dextrose 5%?

Aminosyn II 3.5% in Dextrose 5% is a parenteral nutrition (PN) product used in hospitals to provide essential amino acids and glucose to patients unable to ingest food orally or enterally. The key drivers are:

• Increase in inpatient and critical care admissions: Rapid growth in hospital stays, especially in intensive care units, expands demand for PN solutions.
• Aging global population: Elderly patients tend to have higher nutritional support needs, driving product consumption.
• Growth in chronic and acute conditions: Conditions like cancer, trauma, and gastrointestinal disorders necessitate long-term nutrition support.
• Rising prevalence of malnutrition in hospitals: Both undernutrition and specific nutritional deficiencies augment demand for specialized PN formulations.
• Regulatory approvals and protocol standardization: Widespread acceptance of PN protocols boosts market access.

How Does Market Competition Impact Supply and Pricing?

Major manufacturers include Fresenius Kabi, ICU Medical, Baxter International, and Sigma-Tau International. The competition influences:

• Pricing pressure: Market saturation and product commoditization lead to aggressive pricing to retain market share.
• Product differentiation: Innovations focus on customization, stability, and compatibility with additives.
• Supply chain considerations: Raw material availability (e.g., amino acids, dextrose) influences procurement costs.

What Are the Financial Trends?

Market revenue estimations for amino acid and dextrose-based PN solutions have shown steady growth.

Year	Estimated Market Size (USD billion)	CAGR (2018-2023)	Key Regions
2018	1.5	N/A	North America, Europe
2021	2.0	10%	North America, Asia-Pacific
2023	2.4	Projected 9%	Global

The North American market remains dominant (>50% share) owing to high healthcare expenditure, followed by Europe and Asia-Pacific. The Asian market shows rapid growth rates, driven by expanding healthcare infrastructure and increasing adoption in emerging markets.

What Are the Key Regulatory and Policy Factors?

• FDA approvals: Ensure compliance in the US for hospital procurement.
• EMA approvals: Influence market access in Europe.
• GMP standards: Global quality standards govern manufacturing practices.
• Reimbursement policies: Insurance coverage and hospital procurement policies determine product availability and adoption.

What Is the Outlook for Financial Performance?

Projected revenues are expected to grow at a compound annual growth rate (CAGR) of approximately 8-10% over the next five years, driven primarily by:

• Increased hospital admissions.
• Expansion into emerging markets.
• Product innovation, such as sterile formulations and additive compatibility.

Profit margins may face pressure from sourcing raw materials and competitive pricing strategies. Investment in manufacturing efficiency improvements can mitigate margin erosion.

Risks Affecting Market Growth and Financial Trajectory

• Raw material price volatility: Amino acids and dextrose prices fluctuate with global supply chains.
• Regulatory changes: Stringent policies could delay product launches.
• Market saturation: As the product reaches maturity, growth slows.
• Alternative nutrition methods: Developments in enteral and oral nutritional therapies may reduce PN reliance.

Key Takeaways

• The global market for amino acid/dextrose PN solutions is expanding due to increased hospitalizations and aging populations.
• North America dominates, but Asia-Pacific offers significant growth opportunities.
• Competition mainly affects pricing and product differentiation.
• Revenue growth is estimated at approximately 8-10% annually over the next five years.
• Regulatory compliance and raw material costs are primary influences on financial performance.

FAQs

1. What is the primary use case for Aminosyn II 3.5% in Dextrose 5%?
   It is used for parenteral nutrition in patients unable to meet nutritional needs orally or enterally, such as critically ill or postoperative patients.

2. How does market competition affect pricing?
   Intense competition leads to price reductions and pressure on profit margins.

3. Are emerging markets expanding access to Aminosyn II?
   Yes, especially in Asia-Pacific, where healthcare infrastructure investments increase adoption.

4. What are the main regulatory hurdles?
   Product approval processes by FDA and EMA, plus adherence to GMP standards, can impact market entry and continuity.

5. What factors could hinder market growth?
   Raw material cost fluctuations, regulatory delays, and competition from alternative nutritional therapies pose risks.

---

References

[1] MarketsandMarkets. (2022). Parenteral Nutrition Market by Product, Application, and Geography.
[2] Global Market Insights. (2023). Parenteral Nutrition Market Size and Trends.
[3] U.S. Food and Drug Administration. (2021). Guidelines for Parenteral Nutrition Products.